Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD Study of MSB11456 (Tyenne) vs Actemra/RoActemra in Healthy Adults
NCT03282851Phase 1Completed
- Sponsor
- Fresenius Kabi
- Start
- Nov 2017
- Primary completion
- Oct 2019
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of leuprolide in rheumatoid arthritis (RA) (3 arms), sponsored by Fresenius Kabi. Primary endpoints: Area Under the Serum Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration at Day 48, Area Under the Serum Concentration-Time Curve From Time Zero to Infinity at Day 48 and 1 more. Started Nov 2017; status: completed.
02
Drugs
leuprolide
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03282851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03282851.